REGENXBIO Conference Call Scheduled for November to Review Q3 2026 Results

REGENXBIO Inc. to Host Conference Call

REGENXBIO Inc. (Nasdaq: RGNX), a leading biotechnology firm, has announced an upcoming conference call scheduled for November 5, 2026, at 8:00 a.m. ET. This call is aimed at discussing the company's financial results for the third quarter of 2026, concluding on September 30, along with various operational highlights that have transpired during the period.

Listeners interested in the call can easily register for the webcast through REGENXBIO’s investor homepage. For analysts who wish to actively participate in the question and answer segment of the call, a separate registration link is provided, ensuring an interactive dialogue post-presentation. Furthermore, for those unable to attend live, the company plans to offer a replay of the webcast approximately two hours after the event's conclusion, making the insights accessible to a broader audience.

A Brief on REGENXBIO

Founded in 2009, REGENXBIO is at the forefront of biotechnology, specifically focused on harnessing the curative potential of gene therapy, especially using its proprietary AAV (Adeno-Associated Virus) platform. The company has built a strong pipeline of one-time therapies aimed at treating a variety of rare and retinal diseases. Among these, the development of RGX-202 targets Duchenne Muscular Dystrophy, while clemidsogene lanparvovec (RGX-121) and RGX-111 address MPS II and MPS I conditions in partnership with Nippon Shinyaku.

Additionally, REGENXBIO is collaborating with AbbVie on surabgene lomparvovec (ABBV-RGX-314), which is designed for the treatment of wet Age-Related Macular Degeneration (AMD) and diabetic retinopathy. The company's innovative treatments have seen wide application, with thousands of patients having received therapies derived from its AAV platform, including notable products like Novartis' ZOLGENSMA® and ITVISMA®.

The upcoming conference call is significant as it not only showcases the financial progress but also brings attention to the advancements in their therapeutic pipelines that could lead to substantial life improvements for patients worldwide. As the event approaches, REGENXBIO encourages participants to log in approximately 15 minutes prior to the start to ensure a smooth entry into the session.

Conclusion

As REGENXBIO continues to drive innovation in gene therapy, keen observers and stakeholders are looking forward to the insights and detailed discussion that will emerge from the upcoming October conference call. The company's commitment to transforming healthcare through advanced genetic treatments positions it as a key player within the biotechnology sector.

For further information, please visit the REGENXBIO website.